Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Analgesia and Pain Management

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...

Opioid Receptors: Overview

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...

Drug Abuse and Addiction: Pharmacological Phenomena

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...

Oral Drug Delivery Systems: Continuous-Release Systems

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Practical Technology for Expanding and Improving Substance Use Disorder Treatment: Telehealth, Remote Monitoring, and Digital Health Interventions.

The Psychiatric clinics of North America·2022

Same author

Thirty Years of TheASAMCriteria: A Report Card.

The Psychiatric clinics of North America·2022

Same author

Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence.

Journal of addiction medicine·2017

Same author

A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical Practice in Missouri.

Journal of substance abuse treatment·2016

Same author

Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?

Journal of addiction medicine·2015

Same author

Extended-Release Naltrexone for Alcohol and Opioid Problems in Missouri Parolees and Probationers.

Journal of substance abuse treatment·2015

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

Published on: January 29, 2017

Intramuscular extended-release naltrexone: current evidence.

David R Gastfriend¹

¹Alkermes, Inc., Waltham, Massachusetts 02451-1420, USA. david.gastfriend@alkermes.com

Annals of the New York Academy of Sciences

|January 29, 2011

Summary

This summary is machine-generated.

Extended-release naltrexone (XR-NTX) improves abstinence in alcohol and opioid dependence. This treatment shows efficacy in reducing cravings and relapse, with good safety and cost-effectiveness.

More Related Videos

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

A Conflict Model of Reward-seeking Behavior in Male Rats

A Conflict Model of Reward-seeking Behavior in Male Rats

Published on: February 20, 2019

Related Experiment Videos

Last Updated: Jun 4, 2026

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

Published on: January 29, 2017

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

A Conflict Model of Reward-seeking Behavior in Male Rats

A Conflict Model of Reward-seeking Behavior in Male Rats

Published on: February 20, 2019

Area of Science:

Pharmacology
Neuroscience
Addiction Medicine

Background:

Extended-release naltrexone (XR-NTX) was developed to improve adherence in addiction treatment.
It is approved for alcohol and opioid dependence disorders.

Purpose of the Study:

To review the efficacy and safety of XR-NTX in treating alcohol and opioid dependence.
To explore its potential in treating stimulant dependence.

Main Methods:

Clinical trial data review
fMRI studies on cue salience
Retrospective claims analyses for cost-effectiveness

Main Results:

XR-NTX increased abstinence rates in alcohol-dependent adults.
It attenuated the salience of alcohol cues and showed efficacy during high cue-exposure periods.
XR-NTX demonstrated efficacy in maintaining abstinence, improving retention, decreasing craving, and preventing relapse in opioid dependence.
Safety and tolerability were generally good, with no adverse hepatic impact.
Retrospective analyses indicated cost savings and reduced service utilization.

Conclusions:

XR-NTX is effective for alcohol and opioid dependence, improving abstinence and reducing cravings.
It is a feasible treatment option in various healthcare settings.
Further research is ongoing for stimulant dependence treatment.